ContributorsPublishersAdvertisers

Biogen's stock is up on strong earnings; new Alzheimer's drug had $300,000 in sales in Q3

MarketWatch
MarketWatch
 2021-10-20
Cover picture for the article

Shares of Biogen Inc. were up 1.8% in premarket trading on Wednesday after the company beat expectations for the third quarter despite lower-than-expected utilization of Aduhelm, its controversial and closely watched new Alzheimer's disease treatment. Biogen had net income of $329.2 million, or $2.22 per share, in the third quarter...

www.marketwatch.com

Comments / 0

Comments / 0